Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure

Wong, Rachel H. X.; Howe, Peter R. C.; Buckley, Jonathan D.; Coates, Alison M.; Kunz, Iris; Berry, Narelle M.

doi:10.1016/j.numecd.2010.03.003

Cited by 253 publications

(228 citation statements)

References 30 publications

Supporting

Mentioning

220

Contrasting

Unclassified

Order By: Relevance

“…FMD is widely used in evaluating endothelial function and decreased FMD is a risk factor for cardiovascular disease in older adults [64] and low risk populations [65]. Wong et al [66] found FMD increased 45 min following 30 mg, 90 mg, and 270 mg dosages of trans-resveratrol in 19 overweight/ obese individuals with unmedicated borderline hypertension. FMD significantly increased compared to placebo following each of the three dosages, while baseline arterial diameter remained unchanged.…”

Section: Cardiovascular Effectsmentioning

confidence: 99%

“…As a whole, the current literature suggests that resveratrol is safe and may promote beneficial changes in health, although further research is necessary. This review identified six peerreviewed publications [31,51,52,57,66,85], one research announcement [58] and one major professional presentation [59] (that has not yet been published in a peer-reviewed form) that measured end points beyond bioavailability and safety, with the longest study being 6 wk in duration. While findings of improved insulin resistance, blood flow, and decreased oxidative stress and inflammation combined with excellent short-term safety point to a promising future, there is no way of knowing if these will translate into long-term health benefits until well-controlled studies are performed.…”

Section: Current Limitations To Human Clinical Trial Datamentioning

confidence: 99%

“…In many cases, the other compounds present in the matrix used to deliver resveratrol may enhance its action, or produce their own effects [86]. For instance, 270 mg transresveratrol [66] and 600 mg of grapeskin extract containingo50 mg trans-resveratrol [87] have been found to comparably increase FMD of the brachial artery one hour following consumption, whereas 90 mg trans-resveratrol [66] tends to have a smaller effect. Ghanim's two studies illustrate this point in that six weeks of P. cuspidatum supplementation did not significantly alter either TLR4 mRNA or protein expression [51], whereas one meal with a resveratrol and grapeskin polyphenol supplement significantly increased TLR4 protein expression [52].…”

Section: Current Limitations To Human Clinical Trial Datamentioning

confidence: 99%

See 2 more Smart Citations

Resveratrol and health – A comprehensive review of human clinical trials

Smoliga

Baur

Hausenblas

2011

Molecular Nutrition Food Res

489

308

View full text Add to dashboard Cite

In the past decade, the small polyphenol resveratrol has received widespread attention as either a potential therapy or as a preventive agent for numerous diseases. Studies using purified enzymes, cultured cells, and laboratory animals have suggested that resveratrol has anti-aging, anti-carcinogenic, anti-inflammatory, and anti-oxidant properties that might be relevant to chronic diseases and/or longevity in humans. Although the supporting research in laboratory models is quite substantial, only recently data has emerged to describe the effects of resveratrol supplementation on physiological responses in humans. The limited number of human clinical trials that are available has largely described various aspects of resveratrol's safety and bioavailability, reaching a consensus that it is generally well-tolerated, but have poor bioavailability. Very few published human studies have explored the ability of resveratrol to achieve the physiological benefits that have been observed in laboratory models, although many clinical trials have recently been initiated. This review aims to examine the current state of knowledge on the effects of resveratrol on humans and to utilize this information to develop further guidelines for the implementation of human clinical trials.

show abstract

Section: Cardiovascular Effectsmentioning

confidence: 99%

Section: Current Limitations To Human Clinical Trial Datamentioning

confidence: 99%

Section: Current Limitations To Human Clinical Trial Datamentioning

confidence: 99%

See 1 more Smart Citation

Resveratrol and health – A comprehensive review of human clinical trials

Smoliga

Baur

Hausenblas

2011

Molecular Nutrition Food Res

489

308

View full text Add to dashboard Cite

show abstract

“…The follow-up period ranged from 4 to 48 weeks18,19, and in spite of all the studies being randomized clinical trials, six were of the crossover type 16,18,20,22,23,26 ,and four were parallel studies 17,19,21,24 . Of the ten studies selected, six used capsules composed of resveratrol only 17,18,19,22,23,26 , in different doses (10 mg, 150 mg, 8 or 16 mg, 100mg, 30 or 90 or 270mg or 150mg respectively) and four made use of capsules mixed with different compounds 16,20,21,24 , including resveratrol.…”

Section: Characteristics Of Interventionsmentioning

confidence: 99%

“…Of the ten studies selected, six used capsules composed of resveratrol only 17,18,19,22,23,26 , in different doses (10 mg, 150 mg, 8 or 16 mg, 100mg, 30 or 90 or 270mg or 150mg respectively) and four made use of capsules mixed with different compounds 16,20,21,24 , including resveratrol. The quantity of resveratrol used in the intervention fluctuated from minimum concentrations of 0.54 mg⁄day21, to doses of 36g⁄day16.…”

Section: Characteristics Of Interventionsmentioning

confidence: 99%

Use of Resveratrol in Cardiovascular Diseases Prevention: A Systematic Review

Góes

Fraga

Ladeia

2017

BJMHH

View full text Add to dashboard Cite

| Resveratrol, a polyphenolic compound found in blackberry and red wine, has properties that prevent the development of atherosclerosis, and therefore, cardiovascular disease. The aim of this study was, through a systematic review, to assess whether resveratrol reduces the incidence of cardiovascular events and improves inflammation and endothelial dysfunction in individuals at risk. Searches were conducted in databases such as LILACS, PubMed,SCIELO and selected randomized controlled trials in humans, including the use of resveratrol in the prevention of cardiovascular events or in the improvement of inflammation and endothelial function. The final sample consisted of 10 items. Of the four studies that analyzed the flow-mediated dilatation of the brachial artery, all showed significant improvement in endothelial function after the use of resveratrol, compared with placebo. In the 7 studies that evaluated subclinical inflammation, there were differences, 3 studies showed significant decreases in the values of TNF-α, 2 showed significant changes in plasma levels of C-reactive protein and interleukin 6 (IL-6), while 1 didn't showed changes in TNF-α and IL-6. In conclusion, resveratrol is capable of improving endothelial function when compared with placebo. However, it was not possible to infer an improvement or not in the parameters concerning endothelial inflammation, since the data extracted from the studies were insufficient. Moreover, it was not possible to evaluate the use of resveratrol in the improvement of survival, infarction or reduction in mortality, since there were no records in the literature of randomized controlled trials that analyzed the effect of resveratrol use on clinical outcomes in humans.

show abstract

Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease

et al. 2017

View full text Add to dashboard Cite

IMPORTANCE Research shows that resveratrol, a sirtuin activator in red wine, improves exercise endurance and skeletal-muscle oxidative metabolism in animals and may enhance vascular function in humans. Resveratrol supplement sales exceed $30 million annually in the United States, but few data are available regarding its efficacy in humans. OBJECTIVE To determine whether resveratrol, 125 mg/d or 500 mg/d, improves the 6-minute walk performance in patients with peripheral artery disease (PAD). DESIGN, SETTING, AND PARTICIPANTS This parallel-design, double-blind, randomized clinical trial, called Resveratrol to Improve Outcomes in Older People With PAD (RESTORE), was conducted at Northwestern University. Sixty-six participants 65 years or older with PAD were randomized to receive a daily capsule of resveratrol, 125 mg or 500 mg, or placebo for 6 months. Participants were randomized using a randomly permuted block method stratified by baseline 6-minute walk test performance. This trial was conducted between January 1, 2015, and August 5, 2016, and data analyses were performed according to the intention-to-treat concept. INTERVENTIONS Administration of resveratrol, 125 or 500 mg/d, or placebo once daily. MAIN OUTCOMES AND MEASURES The primary outcome measure was the change in 6-minute walk distance at the 6-month follow-up. One of the secondary outcomes was change in maximal treadmill walking time. Because of the preliminary nature of the trial, the a priori power calculation used a 1-sided test with a significance level of P < .10. RESULTS The 66 participants were predominantly men (45 [68%]), had a mean (SD) age of 74.4 (6.6) years, and had a mean (SD) ankle brachial index of 0.67 (0.18). Sixty-four (97%) completed follow-up. Six-month mean (SE) changes in 6-minute walk distance were 4.6 (8.1) m for the 125-mg resveratrol group, −12.8 (7.5) m for the 500-mg resveratrol group, and −12.3 (7.9) m for the placebo group (P = .07 for the 125-mg resveratrol group vs placebo; P = .96 for the 500-mg resveratrol group vs placebo). Six-month mean (SE) changes in maximal treadmill walking time were 0.5 (2.3) minutes for the 125-mg resveratrol group, −0.6 (2.1) minutes for the 500-mg resveratrol group, and 0.4 (2.1) minutes for the placebo group (P = .18 for the 125-mg resveratrol group vs placebo; P = .12 for the 500-mg resveratrol group vs placebo). CONCLUSIONS AND RELEVANCE The RESTORE trial found no consistent evidence that resveratrol improves walking performance in patients 65 years or older with PAD. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT02246660

show abstract

Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure

Cited by 253 publications

References 30 publications

Resveratrol and health – A comprehensive review of human clinical trials

Resveratrol and health – A comprehensive review of human clinical trials

Use of Resveratrol in Cardiovascular Diseases Prevention: A Systematic Review

Effect of Resveratrol on Walking Performance in Older People With Peripheral Artery Disease

Contact Info

Product

Resources

About